𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore

✍ Scribed by Lacey, L. F. (author);Gane, E. (author)

Book ID
108886020
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
267 KB
Volume
14
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

New perspectives in the treatment of HBe
New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B
✍ Thomas Berg πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 141 KB πŸ‘ 2 views

BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term

Long-term follow-up of peginterferon and
Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B
✍ Henry Lik-Yuen Chan; Alex Yui Hui; Vincent Wai-Sun Wong; Angel Mei-Ling Chim; Ma πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 141 KB πŸ‘ 2 views

We have previously demonstrated that combination peginterferon and lamivudine treatment has superior antiviral efficacy to lamivudine monotherapy in chronic hepatitis B. In this study, we investigated the long-term posttreatment virological response to this combination treatment. Sustained virologic